Security Reports > Esperion Therapeutics

Esperion Therapeutics
Data Breaches, Cyber Attacks and Security Report

https://esperion.com  ᛫  Biotech & Pharmaceuticals
Last updated August 14, 2020

Esperion Therapeutics Security Rating

${grade.letter}
${cstarScore}
/ 950

UpGuard's Cyber Security Ratings range from 0 to 950. The higher the score, the more likely Esperion Therapeutics is implementing good security practices.

Company Information

Company:
${companyName}
Valuation:
${marketCap}
Employees:
${employees}
Location:
${country}
CEO:
${ceo}

About Esperion Therapeutics

Esperion Therapeutics, Inc. is a public, American pharmaceutical company focused on the development of a first-in-class, orally available, small molecule designed to significantly lower elevated levels of LDL-C - with the reduced potential for muscle-related side effects associated with statin use.


Data Breaches and Security News


Security Report for Esperion Therapeutics

Want a security rating for your organization?

This report shows a preliminary security rating for Esperion Therapeutics. UpGuard scans billions of digital assets daily, in depth, across thousands of vectors. Data leak detection, vulnerability scanning and identity breach detection are just some of the advanced capabilities offered by the UpGuard platform.

Get a deeper scan

Related posts

Read more about the latest issues in cybersecurity

More security reports

Compare Esperion Therapeutics's security performance with other companies